We hope you have had the chance to watch the successful AACC webinar The Use of Biomarkers in Chronic Kidney Disease and the Novel Disorder Shrunken Pore Syndrome with Dr. Anders Grubb. In this webinar Dr. Grubb is discussing using creatinine and cystatin C to diagnose Shrunken Pore Syndrome (SPS).
Dr. Grubb and his colleagues described SPS for the first time in an article in Scandinavian Journal of Clinical and Laboratory Investigation in 2015. In the AACC CLN Stat article To Catch Shrunken Pore Syndrome, Measure Cystatin C from July 2020, Dr. Grubb states that both cystatin C and creatinine are needed to diagnose SPS. Dr. Grubb therefore recommends to include the determination of cystatin C in the KDIGO guidelines which are from 2012, three years before SPS was discovered.
Since the launch of the webinar September 2019 more studies have been published regarding the novel shrunken pore syndrome (SPS):
Want to know more about Gentian’s Cystatin C Immunoassay? Watch this webinar with Gentian’s Product Manager for Cystatin C, Gaute Tangen.
For more details on cystatin C in general or the Gentian Cystatin C Immunoassay please contact us at marketing@gentian.com or fill out the form below:
Shrunken pore syndrome is now described on Wikipedia both in English and in Swedish: